Evidence map›Paper›PMID 29568051›Full record

ReviewNature chemistry2018

Organic synthesis provides opportunities to transform drug discovery.

David C Blakemore, Luis Castro, Ian Churcher, David C Rees, Andrew W Thomas, David M Wilson, Anthony Wood

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 431 papers.

0numbers the graph read from it
0cells of the map it votes in
431citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

431 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. A General Photoredox Platform for the Hydroarylation of Olefins.Journal of the American Chemical Society · 2026
    Article
  8. Article
  9. Article
  10. Base-Free C-N Cross-Electrophile Coupling.Journal of the American Chemical Society · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Lactam Framework Editing via Formal Methylene Deletion.Journal of the American Chemical Society · 2026
    Article
  17. Review
  18. Article
  19. Article
  20. Shape-Conserving Atom Replacements.Chemical reviews · 2026
    Review

371 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

David C BlakemoreMedicinal Sciences, Pfizer, Inc. Eastern Point Road, Groton, CT, USA.
Luis CastroUCB, Slough, Berkshire, UK.
Ian ChurcherGSK Medicines Research Centre, Stevenage, UK.
David C ReesAstex Pharmaceuticals, Cambridge, UK. david.rees@astx.com.
Andrew W ThomasRoche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
David M WilsonOncology, IMED Biotech Unit, AstraZeneca, Cambridge, UK.
Anthony WoodMedicinal Sciences, Pfizer, Inc., Cambridge, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite decades of ground-breaking research in academia, organic synthesis is still a rate-limiting factor in drug-discovery projects. Here we present some current challenges in synthetic organic chemistry from the perspective of the pharmaceutical industry and highlight problematic steps that, if overcome, would find extensive application in the discovery of transformational medicines. Significant synthesis challenges arise from the fact that drug molecules typically contain amines and N-heterocycles, as well as unprotected polar groups. There is also a need for new reactions that enable non-traditional disconnections, more C-H bond activation and late-stage functionalization, as well as stereoselectively substituted aliphatic heterocyclic ring synthesis, C-X or C-C bond formation. We also emphasize that syntheses compatible with biomacromolecules will find increasing use, while new technologies such as machine-assisted approaches and artificial intelligence for synthesis planning have the potential to dramatically accelerate the drug-discovery process. We believe that increasing collaboration between academic and industrial chemists is crucial to address the challenges outlined here.

Indexed as

Chemistry Techniques, SyntheticDrug DiscoveryPharmaceutical PreparationsPharmaceutical Preparations

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.